Molecular insight into substrate recognition by human cytosolic sialidase NEU2.
Sialidases or neuramidases are glycoside hydrolases removing terminal sialic acid residues from sialo-glycoproteins and sialo-glycolipids. Viral neuraminidases (NAs) have been extensively characterized and represent an excellent target for antiviral therapy through the synthesis of a series of competitive inhibitors that block the release of newly formed viral particles from infected cells. The human cytosolic sialidase NEU2 is the only mammalian enzyme structurally characterized and represents a valuable model to study the specificity of novel NA inhibitory drugs. Moreover, the availability of NEU2 3D structure represents a pivotal step toward the characterization of the molecular basis of natural substrates recognition by the enzyme. In this perspective, we have carried out a study of molecular docking of NEU2 active site using natural substrates of increasing complexity. Moreover, selective mutations of the residues putatively involved into substrate(s) interaction/recognition have been performed, and the resulting mutant enzymes have been preliminary tested for their catalytic activity and substrate specificity. We found that Q270 is involved in the binding of the disaccharide α(2,3) sialyl-galactose, whereas K45 and Q112 bind the distal glucose of the trisaccharide α(2,3) sialyl-lactose, corresponding to the oligosaccharide moiety of GM3 ganglioside. In addition, E218, beside D46, is proved to be a key catalytic residue, being, together with Y334, the second member of the nucleophile pair required for the catalysis. Overall, our results point out the existence of a dynamic network of interactions that are possibly involved in the recognition of the glycans bearing sialic acid.
Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Milano, Italy.
Alessandra
A
Mozzi
Pietro
P
Mazzacuva
Giuseppe
G
Zampella
Matilde Emma
ME
Forcella
Paola Alessandra
PA
Fusi
Eugenio
E
Monti
D020134:Catalytic Domain; D003198:Computer Simulation; D018360:Crystallography, X-Ray; D003600:Cytosol / Q000737:chemistry*; D004789:Enzyme Activation; D057075:Enzyme Assays; D004926:Escherichia coli / Q000737:chemistry / Q000235:genetics; D005690:Galactose / Q000031:analogs & derivatives / Q000737:chemistry; D006801:Humans; D006923:Hymecromone / Q000031:analogs & derivatives / Q000737:chemistry; D053118:Influenza A Virus, H1N1 Subtype / Q000201:enzymology; D007785:Lactose / Q000031:analogs & derivatives / Q000737:chemistry; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D009439:Neuraminidase / Q000737:chemistry* / Q000235:genetics; D011485:Protein Binding; D012794:Sialic Acids / Q000737:chemistry; D013379:Substrate Specificity
D012794:Sialic Acids; C542734:sialylalpha(2-3)galactose; C000020:N-acetylneuraminoyllactose; D006923:Hymecromone; C021224:2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid; C403285:NEU2 protein, human; D009439:Neuraminidase; D007785:Lactose; D005690:Galactose